{
    "2021-03-03": [
        [
            {
                "time": "2022-10-15",
                "original_text": "Vir Stock Craters On Weak Results For Glaxo-Partnered Covid Treatment",
                "features": {
                    "keywords": [
                        "Vir",
                        "Stock",
                        "Craters",
                        "Weak Results",
                        "Glaxo-Partnered",
                        "Covid Treatment"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2022-10-15",
                "original_text": "Vir Shares Plummeted Today. What to Know.",
                "features": {
                    "keywords": [
                        "Vir",
                        "Shares",
                        "Plummeted"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2022-10-15",
                "original_text": "Vir Biotechnology Shares Are Trading Lower As COVID-19 Study VIR-7831 Arm To Stop Enrollment",
                "features": {
                    "keywords": [
                        "Vir Biotechnology",
                        "Shares",
                        "Trading Lower",
                        "COVID-19 Study",
                        "VIR-7831",
                        "Stop Enrollment"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2022-10-15",
                "original_text": "Eli Lilly/Incyte's Baricitinib Shows Benefit In Patchy Hair Loss Disorder",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Incyte",
                        "Baricitinib",
                        "Patchy Hair Loss",
                        "Benefit"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2022-10-15",
                "original_text": "Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial",
                "features": {
                    "keywords": [
                        "Baricitinib",
                        "JAK-Inhibitor",
                        "Hair Regrowth",
                        "Phase 3",
                        "Alopecia Areata",
                        "Trial"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}